Tags

Type your tag names separated by a space and hit enter

Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis.
Allergy Asthma Proc. 2007 Nov-Dec; 28(6):716-23.AA

Abstract

Seasonal allergic rhinitis (SAR) treatment should reduce symptoms and help patients resume normal function. This study was performed to determine the effect of olopatadine (Olo) nasal spray on symptoms, quality of life (QoL), work, and activities of SAR patients. A pooled analysis was conducted of two Institutional Review Board-approved, randomized, double-blind clinical trials that compared 2-week treatment with Olo 0.6% and Olo 0.4% to placebo. Symptoms were assessed with the Total Nasal Symptom Score (TNSS) from daily diaries. Health outcomes were measured by the Work Productivity and Activity Impairment Questionnaire-Allergy Specific (WPAI-AS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The studies included 1240 SAR patients with a mean age of 37 years; 64% were women. TNSS and RQLQ improvements were significantly different from placebo: TNSS, Olo 0.6% (p < 0.0001) and Olo 0.4% (p < 0.0037); RQLQ, Olo 0.6% (p < 0.001) and Olo 0.4% (p < 0.05). WPAI-AS improvements also were significant for overall work impact and activity impairment in the Olo 0.6% (p < 0.001) and Olo 0.4% (p < 0.05). Correlations between Olo 0.6% TNSS scores and work impact were r = 0.45 (p < 0.0001); activities, r = 0.55 (p < 0.0001); and RQLQ score, r = 0.61 (p < 0.0001), indicating that symptom reduction with Olo therapy was associated with improvements in function and QoL. Adverse events were nonserious and infrequent in all treatment groups. The most frequent adverse events were unpleasant taste and headache. This analysis indicates that Olo is a safe and effective intranasal treatment and is associated with significant improvement in QoL and ability to perform work and conduct usual activities of SAR patients.

Authors+Show Affiliations

Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, Texas 76134, USA. Carol.Fairchild@alconlabs.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18201438

Citation

Fairchild, Carol J., et al. "Comprehensive Report of the Efficacy, Safety, Quality of Life, and Work Impact of Olopatadine 0.6% and Olopatadine 0.4% Treatment in Patients With Seasonal Allergic Rhinitis." Allergy and Asthma Proceedings, vol. 28, no. 6, 2007, pp. 716-23.
Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2007;28(6):716-23.
Fairchild, C. J., Meltzer, E. O., Roland, P. S., Wells, D., Drake, M., & Wall, G. M. (2007). Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy and Asthma Proceedings, 28(6), 716-23. https://doi.org/10.2500/aap.2007.28.3062
Fairchild CJ, et al. Comprehensive Report of the Efficacy, Safety, Quality of Life, and Work Impact of Olopatadine 0.6% and Olopatadine 0.4% Treatment in Patients With Seasonal Allergic Rhinitis. Allergy Asthma Proc. 2007 Nov-Dec;28(6):716-23. PubMed PMID: 18201438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. AU - Fairchild,Carol J, AU - Meltzer,Eli O, AU - Roland,Peter S, AU - Wells,David, AU - Drake,Margaret, AU - Wall,G Michael, PY - 2008/1/19/pubmed PY - 2008/3/5/medline PY - 2008/1/19/entrez SP - 716 EP - 23 JF - Allergy and asthma proceedings JO - Allergy Asthma Proc VL - 28 IS - 6 N2 - Seasonal allergic rhinitis (SAR) treatment should reduce symptoms and help patients resume normal function. This study was performed to determine the effect of olopatadine (Olo) nasal spray on symptoms, quality of life (QoL), work, and activities of SAR patients. A pooled analysis was conducted of two Institutional Review Board-approved, randomized, double-blind clinical trials that compared 2-week treatment with Olo 0.6% and Olo 0.4% to placebo. Symptoms were assessed with the Total Nasal Symptom Score (TNSS) from daily diaries. Health outcomes were measured by the Work Productivity and Activity Impairment Questionnaire-Allergy Specific (WPAI-AS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The studies included 1240 SAR patients with a mean age of 37 years; 64% were women. TNSS and RQLQ improvements were significantly different from placebo: TNSS, Olo 0.6% (p < 0.0001) and Olo 0.4% (p < 0.0037); RQLQ, Olo 0.6% (p < 0.001) and Olo 0.4% (p < 0.05). WPAI-AS improvements also were significant for overall work impact and activity impairment in the Olo 0.6% (p < 0.001) and Olo 0.4% (p < 0.05). Correlations between Olo 0.6% TNSS scores and work impact were r = 0.45 (p < 0.0001); activities, r = 0.55 (p < 0.0001); and RQLQ score, r = 0.61 (p < 0.0001), indicating that symptom reduction with Olo therapy was associated with improvements in function and QoL. Adverse events were nonserious and infrequent in all treatment groups. The most frequent adverse events were unpleasant taste and headache. This analysis indicates that Olo is a safe and effective intranasal treatment and is associated with significant improvement in QoL and ability to perform work and conduct usual activities of SAR patients. SN - 1088-5412 UR - https://www.unboundmedicine.com/medline/citation/18201438/Comprehensive_report_of_the_efficacy_safety_quality_of_life_and_work_impact_of_Olopatadine_0_6_and_Olopatadine_0_4_treatment_in_patients_with_seasonal_allergic_rhinitis_ L2 - https://www.ingentaconnect.com/openurl?genre=article&amp;issn=1088-5412&amp;volume=28&amp;issue=6&amp;spage=716&amp;aulast=Fairchild DB - PRIME DP - Unbound Medicine ER -